Year-end Sale % OFF 
Abstract
The current norm of esophageal treatment includes any combination of surgery, chemotherapy and radiation therapy. The effectiveness of medical intervention has been predominantly assessed by morbidity, mortality and disease-free survival in the past. As patients' life expectancies lengthened from advances in treatment modalities, recent movements have shifted to acknowledge patients' health-related quality of life as an important outcome measure. The general trend for the use of multimodal treatments of esophageal cancer indicates an initial degradation of many aspects of HRQoL; however, without postoperative recovery delay related to neoadjuvant treatment. Several recent studies aimed to define aspects of HRQoL as prognostic indicators of esophageal cancer patients that may influence survival. It is imperative for practicing physicians to discuss these concepts with patients as they may cope with treatment complications more favorably if they are informed.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
